DHR · 10-Q · 2026Q2 · Full report

Biotechnology Demand Trends

DANAHER CORP /DE/ · 2026-07-21 · Importance 49 · Surprise 32 · No source text

Biotechnology segment sales increased 4.0% in the second quarter and 7.5% in the first half of 2026, with core sales growth of 2.5% and 4.5%, respectively. Consumables led growth in both periods, while equipment sales increased in the quarter but declined year to date. Bioprocessing posted low-single-digit quarterly and mid-single-digit year-to-date core growth, driven primarily by improved consumables demand; certain large commercial customers shifted shipment timing out of the quarter. Discovery and medical demand improved, led by consumables purchased by pharma and biopharma customers and a modestly improving academic and research funding environment, while geographically China led growth and North America was weaker.

Key facts

• Biotechnology segment sales for the six-month period ended June 26, 2026 were $3,717 million and $3,462 million for the comparable period in 2025. source
• Biotechnology segment sales for the three-month period ended June 26, 2026 were $1,920 million and $1,850 million for the comparable period in 2025. source
• Biotechnology core sales growth (non-GAAP) was 2.5% for the three-month period ended June 26, 2026 and 4.5% for the six-month period ended June 26, 2026. source
• Price increases in the Biotechnology segment contributed 1.5% to sales growth on a year-over-year basis in both the three and six-month periods. source

Impact estimates